{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:01:48Z","timestamp":1789758108921,"version":"4.0.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":314,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly increased. ICIs have also been associated with disinhibited cytotoxic T cells that damage healthy tissue in multiple organs, causing immune-related adverse events (AEs). Cardiovascular AEs (CVAe) are increasingly reported: myocarditis, Takotsubo syndrome, pericarditis and pericardial effusion, worsening of atherosclerosis, acute coronary syndromes, non-inflammatory heart failure, and ischaemic stroke. They are classified into five grades, based on presenting symptoms, level of cardiac biomarkers, and imaging. Even though myocarditis occurs more frequently than previously thought, clinically relevant myocarditis is a rare irAE compared to other irAE (0.5\u20131.2%). The clinical manifestations range from mild symptoms such as to chest pain, heart failure, and cardiogenic shock. The prognosis is severe, with mortality rates ranging from 25% to 50%. It is frequently associated with the concomitant use of combination of checkpoint inhibitors. The treatment strategies are tripartite: (i) holding ICI to prevent further toxicity, (ii) immunosuppression to alleviate inflammatory changes, and (iii) supportive therapy to address cardiac complications. Glucocorticoids represent the first-line treatment. In hemodynamically unstable patients, treatment with high-dose steroids should be initiated (intravenous methylprednisolone 1000 or 1250\u2009mg oral methylprednisolone during 4 days). ICI-associated pericarditis can be accompanied by no\/mild pericardial effusion up to cardiac tamponade. The treatment is made of nonsteroidal anti-inflammatory drugs and colchicine, corticosteroids if needed, and pericardiocentesis for the large effusions. ICIs could be continued for Grade 1 pericarditis, while temporary suspension of ICI is warranted for more severe cases. There is significant potential for accelerated atherosclerosis with ICIs as a long-term effect, but atherosclerosis-related CVAEs are not frequent, especially during treatment; increasing evidence associates ICIs with progression of atherosclerosis and increased atherosclerotic cardiovascular disease. ICIs can lead to arrhythmias: atrial fibrillation, supraventricular and ventricular tachycardias. Non-inflammatory heart failure syndrome have been observed in ICI-treated patients. Immune checkpoint inhibitors seem to be involved in the development of right ventricular dysfunction and pulmonary arterial hypertension. It is of the outmost importance to improve the collaboration among the different medical figures, such as cardiologists, oncologists, endocrinologists, and immunologists, both in clinical practice and in basic science research, to better recognize these adverse events, to understand their pathophysiological mechanisms, and to improve the overall survival and quality of life of the affected patients.<\/jats:p>","DOI":"10.1002\/ehf2.15281","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:04:37Z","timestamp":1744257877000},"page":"2404-2416","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immune Checkpoint Inhibitors and Cardiovascular Adverse Events"],"prefix":"10.1093","volume":"12","author":[{"given":"Maria Luisa","family":"De Perna","sequence":"first","affiliation":[{"name":"Istituto Cardiocentro Ticino, Department of Cardiology, Ente Ospedaliero Cantonale , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Rigamonti","sequence":"additional","affiliation":[{"name":"Istituto Cardiocentro Ticino, Department of Cardiology, Ente Ospedaliero Cantonale , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Zannoni","sequence":"additional","affiliation":[{"name":"Service de M\u00e9dicine Interne g\u00e9n\u00e9rale, D\u00e9partement de m\u00e9decine interne, Hopitaux Universitaires de Gen\u00e8ve (HUG) , rue Gabrielle-Perret-Gentil 4, Gen\u00e8ve ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Espeli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ente Ospedaliero Cantonale, Istituto Oncologico della Svizzera Italiana , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Moschovitis","sequence":"additional","affiliation":[{"name":"Istituto Cardiocentro Ticino, Department of Cardiology, Ente Ospedaliero Cantonale , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2026021804122520000_ehf215281-bib-0001","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am CollCardiol"},{"key":"2026021804122520000_ehf215281-bib-0002"},{"key":"2026021804122520000_ehf215281-bib-0003","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"MPH atherosclerosis with immune checkpoint inhibitor therapy evidence","volume":"4","author":"Suero-Abreu","year":"2022","journal-title":"Diag Manag JACC: Cardio Oncol State-of-the-Art Rev"},{"key":"2026021804122520000_ehf215281-bib-0004","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/imj.12653","article-title":"Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities","volume":"45","author":"Gedye","year":"2015","journal-title":"Intern Med J"},{"key":"2026021804122520000_ehf215281-bib-0005","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J ImmunotherCancer"},{"key":"2026021804122520000_ehf215281-bib-0006","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026021804122520000_ehf215281-bib-0007","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-023-00986-9","volume-title":"Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure","author":"Gergely","year":"2024"},{"key":"2026021804122520000_ehf215281-bib-0008","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analysis identify melanoma patients-risk for checkpoint-blockade induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"2026021804122520000_ehf215281-bib-0009","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026021804122520000_ehf215281-bib-0010","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-020-00867-1","article-title":"Cardiotoxicity of contemporary anticancer immunotherapy","volume":"22","author":"Dalbo","year":"2020","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026021804122520000_ehf215281-bib-0011","article-title":"Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtypes from four trials","volume":"10","author":"Wolchok","year":"2010","journal-title":"Cancer Immun"},{"key":"2026021804122520000_ehf215281-bib-0012","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804122520000_ehf215281-bib-0013","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D'Souza","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804122520000_ehf215281-bib-0014","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lungcan.2017.07.028","article-title":"Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer","volume":"114","author":"Liu","year":"2017","journal-title":"Lung Cancer"},{"key":"2026021804122520000_ehf215281-bib-0015","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","article-title":"CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes","volume":"101","author":"Love","year":"2007","journal-title":"Circ Res"},{"key":"2026021804122520000_ehf215281-bib-0016","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2026021804122520000_ehf215281-bib-0017","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC scientific document group, 2022 ESC guidelines on cardio-oncology","volume":"43","author":"Lyon","year":"2022","journal-title":"Euro Heart J"},{"key":"2026021804122520000_ehf215281-bib-0018","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00395-024-01088-4","article-title":"Effects of sex and obesity on immune checkpoint inhibition-related cardiac systolic dysfunction in aged mice","volume":"120","author":"Sayour","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"2026021804122520000_ehf215281-bib-0019","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"JACC"},{"key":"2026021804122520000_ehf215281-bib-0020","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ahj.2013.07.004","article-title":"High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men","volume":"166","author":"Eggers","year":"2013","journal-title":"Am Heart J"},{"key":"2026021804122520000_ehf215281-bib-0021","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jacc.2017.05.062","article-title":"High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants","volume":"70","author":"Willeit","year":"2017","journal-title":"J Am CollCardiol"},{"key":"2026021804122520000_ehf215281-bib-0022","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccl.2019.07.008","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"CardiolClin"},{"key":"2026021804122520000_ehf215281-bib-0023","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804122520000_ehf215281-bib-0024","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaccao.2022.10.007","article-title":"Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy","volume":"4","author":"Tamura","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026021804122520000_ehf215281-bib-0025","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","article-title":"Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis","volume":"4","author":"Vasbinder","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026021804122520000_ehf215281-bib-0026","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061976","article-title":"Skeletal muscle disorders: a non-cardiac source of cardiac troponin T","volume":"146","author":"du Fay de Lavallaz","year":"2022","journal-title":"Circulation"},{"key":"2026021804122520000_ehf215281-bib-0027","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"2026021804122520000_ehf215281-bib-0028","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-mediated adverse events in pts treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J ClinOncol"},{"key":"2026021804122520000_ehf215281-bib-0029","article-title":"Emerging concerns in cardio-oncology: immune checkpoint cardiotoxicity","author":"Balanescu","year":"2019","journal-title":"Am Coll Cardiol"},{"key":"2026021804122520000_ehf215281-bib-0030","doi-asserted-by":"publisher","first-page":"342","DOI":"10.5603\/cj.95175","article-title":"Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology","volume":"31","author":"Chabior","year":"2024","journal-title":"Cardiol J"},{"key":"2026021804122520000_ehf215281-bib-0031","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.614997","article-title":"Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET\/CT","volume":"8","author":"Finke","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026021804122520000_ehf215281-bib-0032","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003594","article-title":"68Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis","volume":"9","author":"Boughdad","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026021804122520000_ehf215281-bib-0033","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: a guide for clinicians","volume":"46","author":"Raschi","journal-title":"Drug Saf"},{"key":"2026021804122520000_ehf215281-bib-0034","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1634\/theoncologist.2019-0040","article-title":"Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the Memorial Sloan Kettering Cancer Center experience","volume":"24","author":"Lee Chuy","year":"2019","journal-title":"Oncologist"},{"key":"2026021804122520000_ehf215281-bib-0035","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint-inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"2026021804122520000_ehf215281-bib-0036","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026021804122520000_ehf215281-bib-0037","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.currproblcancer.2018.07.002","article-title":"Cardiotoxicities associated with immune checkpoint inhibitors","volume":"42","author":"Yang","year":"2018","journal-title":"CurrProbl Cancer"},{"key":"2026021804122520000_ehf215281-bib-0038","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","article-title":"An unknown reaction to pembrolizumab: giant cell arteritis","volume":"28","author":"Micaily","year":"2017","journal-title":"Ann Oncol"},{"key":"2026021804122520000_ehf215281-bib-0039","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology","volume":"119","author":"Chen","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"2026021804122520000_ehf215281-bib-0040","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","article-title":"Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors","volume":"123","author":"Palaskas","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026021804122520000_ehf215281-bib-0041","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026021804122520000_ehf215281-bib-0042","doi-asserted-by":"publisher","DOI":"10.3389\/or.2023.11456","article-title":"Immune checkpoint inhibitors and their cardiovascular adverse effects","volume":"17","author":"Paluri","year":"2023","journal-title":"Oncol Rev"},{"key":"2026021804122520000_ehf215281-bib-0043","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/circulationaha.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"2026021804122520000_ehf215281-bib-0044","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","article-title":"Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports","volume":"70","author":"Inno","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026021804122520000_ehf215281-bib-0045","author":"Common terminology criteria for adverse events (CTCAE) version 5.0"},{"key":"2026021804122520000_ehf215281-bib-0046","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism","volume":"10","author":"Zhou","year":"2019","journal-title":"Diag Manag Front Pharmacol"},{"key":"2026021804122520000_ehf215281-bib-0047","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J Am CollCardiol"},{"key":"2026021804122520000_ehf215281-bib-0048","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy-a report of two cases","volume":"4","author":"Kolla","year":"2016","journal-title":"J ImmunoTherapy Cancer"},{"key":"2026021804122520000_ehf215281-bib-0049","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1161\/circulationaha.120.048708","article-title":"Immune checkpoint inhibitor therapy induces inflammatory activity in large arteries","volume":"142","author":"Calabretta","year":"2020","journal-title":"Circulation"},{"key":"2026021804122520000_ehf215281-bib-0050","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest"},{"key":"2026021804122520000_ehf215281-bib-0051","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"SciImmunol"},{"key":"2026021804122520000_ehf215281-bib-0052","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"2026021804122520000_ehf215281-bib-0053","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0076-5","article-title":"Statins as adjuvants","volume":"18","author":"Bird","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2026021804122520000_ehf215281-bib-0054","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"ArteriosclerThrombVasc Biol"},{"key":"2026021804122520000_ehf215281-bib-0055","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/circulationaha.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"2026021804122520000_ehf215281-bib-0056","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/mco.2018.1765","article-title":"Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: an observational study","volume":"10","author":"Omori","year":"2019","journal-title":"MolClinOncol"},{"key":"2026021804122520000_ehf215281-bib-0057","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"2026021804122520000_ehf215281-bib-0058","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab014","article-title":"Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors","volume":"1","author":"Drobni","journal-title":"Immunother Adv"},{"key":"2026021804122520000_ehf215281-bib-0059","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","volume":"120","author":"Gergely","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"2026021804122520000_ehf215281-bib-0060","doi-asserted-by":"publisher","DOI":"10.1177\/2045894021992236","article-title":"Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation","volume":"11","author":"Mylvaganam","year":"2021","journal-title":"Pulm Circ"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/4\/2404\/66954503\/eschf_12_4_2404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/4\/2404\/66954503\/eschf_12_4_2404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:12:33Z","timestamp":1771405953000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/4\/2404\/8488097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15281","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"2024-10-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}